Shield Therapeutics plc (FRA:1JS)
Germany
· Delayed Price · Currency is EUR 0.102
-0.021 (-17.07%)
At close: Dec 5, 2025
Shield Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 41.5 | 32.18 | 13.09 | 5.5 | 2.06 | 14.18 | Upgrade
|
| Revenue | 41.5 | 32.18 | 13.09 | 5.5 | 2.06 | 14.18 | Upgrade
|
| Revenue Growth (YoY) | 93.23% | 145.93% | 137.95% | 167.36% | -85.50% | 1389.24% | Upgrade
|
| Cost of Revenue | 21.44 | 17.25 | 9.06 | 3.04 | 1.33 | 1.85 | Upgrade
|
| Gross Profit | 20.06 | 14.93 | 4.03 | 2.46 | 0.73 | 12.33 | Upgrade
|
| Selling, General & Admin | 32.84 | 36.01 | 37.96 | 33.65 | 27.28 | 11.75 | Upgrade
|
| Research & Development | 1.88 | 1.89 | 1.81 | 1.32 | 1.08 | 3.52 | Upgrade
|
| Other Operating Expenses | -0.05 | -0.1 | -4.41 | -0.86 | -0.15 | - | Upgrade
|
| Operating Expenses | 34.67 | 37.8 | 35.36 | 34.1 | 28.21 | 15.27 | Upgrade
|
| Operating Income | -14.61 | -22.87 | -31.33 | -31.65 | -27.48 | -2.94 | Upgrade
|
| Interest Expense | -6 | -3.87 | -1.02 | -0.4 | - | - | Upgrade
|
| Interest & Investment Income | 0.23 | 0.27 | 0.52 | 0.04 | 0.02 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.08 | -0.08 | -0.54 | 0.85 | 0.52 | 0.36 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0 | -0.08 | -0.01 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -20.45 | -26.56 | -32.38 | -31.24 | -26.96 | -2.57 | Upgrade
|
| Asset Writedown | - | - | - | -18.11 | - | - | Upgrade
|
| Pretax Income | -20.45 | -26.56 | -32.38 | -49.34 | -26.96 | -2.57 | Upgrade
|
| Income Tax Expense | 0.79 | 0.63 | 0.92 | 0.45 | -0.31 | 1.02 | Upgrade
|
| Earnings From Continuing Operations | -21.24 | -27.18 | -33.29 | -49.79 | -26.65 | -3.59 | Upgrade
|
| Net Income | -21.24 | -27.18 | -33.29 | -49.79 | -26.65 | -3.59 | Upgrade
|
| Net Income to Common | -21.24 | -27.18 | -33.29 | -49.79 | -26.65 | -3.59 | Upgrade
|
| Shares Outstanding (Basic) | 913 | 783 | 723 | 233 | 204 | 117 | Upgrade
|
| Shares Outstanding (Diluted) | 913 | 783 | 723 | 233 | 204 | 117 | Upgrade
|
| Shares Change (YoY) | 19.74% | 8.33% | 209.85% | 14.08% | 74.36% | 0.21% | Upgrade
|
| EPS (Basic) | -0.02 | -0.03 | -0.05 | -0.21 | -0.13 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.03 | -0.05 | -0.21 | -0.13 | -0.03 | Upgrade
|
| Free Cash Flow | 5.05 | -6.81 | -37.37 | -22.66 | -25.23 | -1.91 | Upgrade
|
| Free Cash Flow Per Share | 0.01 | -0.01 | -0.05 | -0.10 | -0.12 | -0.02 | Upgrade
|
| Gross Margin | 48.34% | 46.39% | 30.78% | 44.70% | 35.48% | 86.96% | Upgrade
|
| Operating Margin | -35.20% | -71.08% | -239.44% | -575.49% | -1336.01% | -20.74% | Upgrade
|
| Profit Margin | -51.18% | -84.47% | -254.44% | -905.42% | -1295.46% | -25.32% | Upgrade
|
| Free Cash Flow Margin | 12.17% | -21.15% | -285.56% | -411.98% | -1226.73% | -13.48% | Upgrade
|
| EBITDA | -14.38 | -22.38 | -31.08 | -29.67 | -25.39 | 0.03 | Upgrade
|
| EBITDA Margin | -34.65% | -69.56% | -237.51% | - | - | 0.23% | Upgrade
|
| D&A For EBITDA | 0.23 | 0.49 | 0.25 | 1.97 | 2.09 | 2.97 | Upgrade
|
| EBIT | -14.61 | -22.87 | -31.33 | -31.65 | -27.48 | -2.94 | Upgrade
|
| EBIT Margin | -35.20% | -71.08% | -239.44% | - | - | -20.74% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.